© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 14, 1165-1171,
July 19, 2000
© 2000 Oxford University Press
REPORTS |
Treatment-Associated Leukemia Following Testicular Cancer
Affiliations of authors: L. B. Travis, R. E. Curtis, J. D. Boice, Jr., E. Gilbert, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; M. Andersson, H. Storm, Danish Cancer Society, Copenhagen, Denmark; M. Gospodarowicz, The Princess Margaret Hospital, University of Toronto, ON, Canada; F. E. van Leeuwen, The Netherlands Cancer Institute, Amsterdam; K. Bergfeldt, P. Hall, Karolinska Institute, Stockholm, Sweden; C. F. Lynch, The University of Iowa, Iowa City; B. A. Kohler, Department of Health and Senior Services, Trenton, NJ; T. Wiklund, Helsinki University Central Hospital, Finland; E. Holowaty, E. A. Clarke, Cancer Care Ontario, Toronto; E. Pukkala, Finnish Cancer Registry, Helsinki; D. T. Sleijfer, University of Groningen, The Netherlands; M. Stovall, The University of Texas M. D. Anderson Cancer Center, Houston.
Correspondence to: Lois B. Travis, M.D., Sc.D., National Institutes of Health, Executive Plaza South, Suite 7086, Bethesda, MD 20892.
Background: Men with testicular cancer are at an increased risk of leukemia, but the relationship to prior treatments is not well characterized. The purpose of our study was to describe the risk of leukemia following radiotherapy and chemotherapy for testicular cancer. Methods: Within a population-based cohort of 18 567 patients diagnosed with testicular cancer (from 1970 through 1993), a case–control study of leukemia was undertaken. Radiation dose to active bone marrow and type and cumulative amount of cytotoxic drugs were compared between 36 men who developed leukemia and 106 matched control patients without leukemia. Conditional logistic regression was used to estimate the relative risk of leukemia associated with specific treatments. All P values are two-sided. Results: Radiotherapy (mean dose to active bone marrow, 12.6 Gy) without chemotherapy was associated with a threefold elevated risk of leukemia. Risk increased with increasing dose of radiation to active bone marrow (P for trend = .02), with patients receiving radiotherapy to the chest as well as to the abdominal/pelvic fields accounting for much of the risk at higher doses. Radiation dose to active bone marrow and the cumulative dose of cisplatin (P for trend = .001) were both predictive of excess leukemia risk in a model adjusted for all treatment variables. The estimated relative risk of leukemia at a cumulative dose of 650 mg cisplatin, which is commonly administered in current testicular cancer treatment regimens, was 3.2 (95% confidence interval = 1.5–8.4); larger doses (1000 mg) were linked with statistically significant sixfold increased risks. Conclusions: Past treatments for testicular cancer are associated with an increased risk of leukemia, with evidence for dose–response relationships for both radiotherapy and cisplatin-based chemotherapy. Statistically nonsignificant excesses are estimated for current radiotherapy regimens limited to the abdomen and pelvis: Among 10 000 patients given a treatment dose of 25 Gy and followed for 15 years, an excess of nine leukemias is predicted; cisplatin-based chemotherapy (dose, 650 mg) might result in 16 cases of leukemia. The survival advantage provided by current radiotherapy and chemotherapy regimens for testicular cancer far exceeds the small absolute risk of leukemia.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Powles, D. Robinson, J. Shamash, H. Moller, N. Tranter, and T. Oliver The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis Ann. Onc., March 1, 2008; 19(3): 443 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer Medical Treatment of Advanced Testicular Cancer JAMA, February 13, 2008; 299(6): 672 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Fossa Second Cancers among Survivors of Testicular Cancer: The Emerging Picture ASCO Educational Book, January 1, 2008; 2008(1): 423 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Bajorin The Graying of Testis Cancer Patients: What Have We Learned? J. Clin. Oncol., October 1, 2007; 25(28): 4341 - 4343. [Full Text] [PDF]
|
|
|
|
|
|
A. W. van den Belt-Dusebout, R. de Wit, J. A. Gietema, S. Horenblas, M. W.J. Louwman, J. G. Ribot, H. J. Hoekstra, G. M. Ouwens, B. M.P. Aleman, and F. E. van Leeuwen Treatment-Specific Risks of Second Malignancies and Cardiovascular Disease in 5-Year Survivors of Testicular Cancer J. Clin. Oncol., October 1, 2007; 25(28): 4370 - 4378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Leone, L. Pagano, D. Ben-Yehuda, and M. T. Voso Therapy-related leukemia and myelodysplasia: susceptibility and incidence Haematologica, October 1, 2007; 92(10): 1389 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schairer, M. Hisada, B. E. Chen, L. M. Brown, R. Howard, S. D. Fossa, M. Gail, and L. B. Travis Comparative Mortality for 621 Second Cancers in 29356 Testicular Cancer Survivors and 12420 Matched First Cancers J Natl Cancer Inst, August 15, 2007; 99(16): 1248 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Fossa, E. Gilbert, G. M. Dores, J. Chen, K. A. McGlynn, S. Schonfeld, H. Storm, P. Hall, E. Holowaty, A. Andersen, et al. Noncancer Causes of Death in Survivors of Testicular Cancer J Natl Cancer Inst, April 4, 2007; 99(7): 533 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bhatia, M. D. Krailo, Z. Chen, L. Burden, F. B. Askin, P. S. Dickman, H. E. Grier, M. P. Link, P. A. Meyers, E. J. Perlman, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group Blood, January 1, 2007; 109(1): 46 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Shuryak, R. K. Sachs, L. Hlatky, M. P. Little, P. Hahnfeldt, and D. J. Brenner Radiation-Induced Leukemia at Doses Relevant to Radiation Therapy: Modeling Mechanisms and Estimating Risks J Natl Cancer Inst, December 20, 2006; 98(24): 1794 - 1806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. de Wit and K. Fizazi Controversies in the Management of Clinical Stage I Testis Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5482 - 5492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis The Epidemiology of Second Primary Cancers Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2020 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Travis, S. D. Fossa, S. J. Schonfeld, M. L. McMaster, C. F. Lynch, H. Storm, P. Hall, E. Holowaty, A. Andersen, E. Pukkala, et al. Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors J Natl Cancer Inst, September 21, 2005; 97(18): 1354 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Hofer, T. J. Browne, L. He, R. I. Skotheim, R. A. Lothe, and M. A. Rubin Identification of Two Molecular Groups of Seminomas by Using Expression and Tissue Microarrays Clin. Cancer Res., August 15, 2005; 11(16): 5722 - 5729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Houck, R. Abonour, G. Vance, and L. H. Einhorn Secondary Leukemias in Refractory Germ Cell Tumor Patients Undergoing Autologous Stem-Cell Transplantation Using High-Dose Etoposide J. Clin. Oncol., June 1, 2004; 22(11): 2155 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Worrillow, L. B. Travis, A. G. Smith, S. Rollinson, A. J. Smith, C. P. Wild, E. J. Holowaty, B. A. Kohler, T. Wiklund, E. Pukkala, et al. An Intron Splice Acceptor Polymorphism in hMSH2 and Risk of Leukemia after Treatment with Chemotherapeutic Alkylating Agents Clin. Cancer Res., August 1, 2003; 9(8): 3012 - 3020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Relling, J. M. Boyett, J. G. Blanco, S. Raimondi, F. G. Behm, J. T. Sandlund, G. K. Rivera, L. E. Kun, W. E. Evans, and C.-H. Pui Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment Blood, May 15, 2003; 101(10): 3862 - 3867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Metayer, R. E. Curtis, J. Vose, K. A. Sobocinski, M. M. Horowitz, S. Bhatia, J. W. Fay, C. O. Freytes, S. C. Goldstein, R. H. Herzig, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study Blood, March 1, 2003; 101(5): 2015 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. B. Leonard, L. B. Travis, K. Addya, G. M. Dores, E. J. Holowaty, K. Bergfeldt, D. Malkin, B. A. Kohler, C. F. Lynch, T. Wiklund, et al. p53 Mutations in Leukemia and Myelodysplastic Syndrome after Ovarian Cancer Clin. Cancer Res., May 1, 2002; 8(5): 973 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Travis, M. Gospodarowicz, R. E. Curtis, E. Aileen Clarke, M. Andersson, B. Glimelius, T. Joensuu, C. F. Lynch, F. E. van Leeuwen, E. Holowaty, et al. Lung Cancer Following Chemotherapy and Radiotherapy for Hodgkin's Disease J Natl Cancer Inst, February 6, 2002; 94(3): 182 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Allan, C. P. Wild, S. Rollinson, E. V. Willett, A. V. Moorman, G. J. Dovey, P. L. Roddam, E. Roman, R. A. Cartwright, and G. J. Morgan Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia PNAS, September 5, 2001; (2001) 191211198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Allan, C. P. Wild, S. Rollinson, E. V. Willett, A. V. Moorman, G. J. Dovey, P. L. Roddam, E. Roman, R. A. Cartwright, and G. J. Morgan Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia PNAS, September 25, 2001; 98(20): 11592 - 11597. [Abstract] [Full Text] [PDF]
|
|